Imugene Limited (AU:IMU) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Imugene Limited has announced the dosing of the first Australian patient in its Phase 1b trial of azer-cel, a promising allogeneic CAR T-cell therapy, at the Royal Prince Alfred Hospital in Sydney. This trial aims to offer a faster, off-the-shelf treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, a challenging form of non-Hodgkin’s lymphoma. With successful results from US trials showing complete responses in patients, Imugene is optimistic about expanding the trial across Australia.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
